Our trial of ondansetron as a treatment for hallucinations in Parkinson's is restarting Date 22 November 2024
Parkinson’s UK awards £1m to new research projects Date 5 November 2024 Parkinson’s UK has granted funding to projects aiming to advance our understanding of the causes and symptoms of Parkinson’s, as well as exploring new treatments.
Results from the phase 3 trial of exenatide shared with participants Date 15 October 2024 The results indicate that people in the study who received exenatide did not benefit compared to those who received placebo - suggesting that the drug does not slow down the progression of Parkinson’s.
Pioneering Landmark project launches Date 23 September 2024 Parkinson’s UK led consortium is using big data to accelerate new treatment options, aiming to unlock a cure for Parkinson’s.
We're investing in the Beech Band, a wearable device that aims to manage Parkinson's symptoms Date 20 September 2024 The Beech Band, designed by Carl Beech, is a wearable device showing promising signs of being able to manage symptoms including speech issues, anxiety and gait.
Progress towards a form of adaptable deep brain stimulation Date 19 August 2024 A small study shows that adaptive deep brain stimulation is better than the standard version at controlling movement symptoms day and night for people with Parkinson’s.
Parkinson's UK invests in developing potential new drug with Acurex Biosciences Date 7 August 2024 We're investing £1.6m through our Virtual Biotech programme to drive forward the development of a promising molecule which has the potential to become a drug that slows or stops Parkinson’s.
Results from major study of speech and language therapy for Parkinson’s published Date 11 July 2024 The results found that Lee Silverman Voice Treatment (LSVT LOUD) is more effective than NHS speech and language therapy.
Parkinson’s UK invests in clinical trial of a potential treatment that could protect brain cells Date 2 July 2024 We're providing £1.24m through our Virtual Biotech programme to help test a potential treatment called MTX325 in people with Parkinson’s.
Parkinson's UK invests in first trial of pioneering treatment in people with Parkinson’s Date 1 July 2024 We're providing £1.55m through our Virtual Biotech programme to carry out the first clinical trials to see if HER-096 is safe for people with Parkinson’s and to start exploring its potential benefits.
Caption Researcher in a laboratory £100,000 awarded for research looking at new drug target for Parkinson’s Date 26 June 2024 Parkinson's UK is funding researchers to develop a potential set of drugs against a new target for people with Parkinson's.
